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Abstract. 17-hydroxysteroid dehydrogenase 10 (HSD10) deficiency is a rare X-linked inborn error of isoleucine catabolism.
Although this protein has been genetically implicated in Alzheimer’s disease pathogenesis, studies of amyloid- peptide (A)
in patients with HSD10 deficiency have not been previously reported. We found, in a severely affected child with HSD10
deficiency, undetectable levels of A in the cerebrospinal fluid, together with low expression of brain-derived neurotrophic factor,
-synuclein, and serotonin metabolites. Confirmation of these findings in other patients would help elucidating mechanisms of
synaptic dysfunction in this disease, and highlight the role of A in both early and late periods of life.
Keywords: Amyloid- peptide, cerebrospinal fluid, childhood, HSD10 deficiency, inborn errors of metabolism, neurotransmit-
ters, synaptic proteins
INTRODUCTION
17-hydroxysteroid dehydrogenase (HSD10) is a
multifunctional mitochondrial enzyme with complex
roles [1, 2]. HSD10 deficiency is an X-linked dis-
ease (MIM300256) caused by mutations in HSD17B10
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gene [3]. This disease is characterized by a clinical
picture very different from other organic acidurias:
patients do not develop metabolic crises, but they
follow a neurodegenerative course associated with
mitochondrial dysfunction [4], progressive loss of
skills, epilepsy, optic atrophy, retinopathy, deafness,
and movement disorders [2].
HSD10 is a protein implicated in the pathogenesis
of Alzheimer’s disease (AD) [5, 6]. Although HSD10
has an affinity for amyloid- peptide (A), no studies
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regarding in vivo quantification of A have been
reported in patients with HSD10 deficiency. Moreover
there are no studies concerning normal cerebrospinal
fluid (CSF) A values in the pediatric age. We aimed
to analyze the expression of A in the CSF of an
affected child, compared to a control pediatric popula-
tion. In order to gather more information about synaptic
mechanisms in this disease, neurotransmitters, brain-
derived neurotrophic factor (BDNF; associated with
dendritic growth, and serotoninergic transmission) and
-synuclein (AS; associated with neurotransmitter
release, dopaminergic modulation and neurodegener-
ation) were also included in our study.
PATIENT AND METHODS
Clinical report
The patient is the first child of healthy non-
consanguineous parents. Pregnancy, peripartum, and
first year of life were uneventful (normal psychomo-
tor development: he could walk with support and
was able to say some words). At 13 months, and
within the context of fever and diarrhea, he developed
psychomotor regression (inability to sit unsupported,
loss of normal use of hands), and disclosed abnor-
mal fast erratic ocular movements, non-epileptic
myoclonus, and irritability. Plasma ammonia and
amino acids were normal but lactate concentration
was up to 3 mmol/l (NV: 0.66–1.88 mM/l). Brain
MRI was normal. Because of the initial symptoms,
opsoclonus-myoclonus syndrome was suspected and
dexamethasone (0.8 mg/kg/d IV for 6 days) was
started. Although the patient showed slight improve-
ment, ocular fundus revealed optic atrophy and a
determination of urine organic acids revealed ele-
vation of 3-hydroxy-2-methylbutyryic (48 mmol/mol
creatinine; CV 5–12) and tiglylglycine (44 mmol/mol
creatinine; CV <5). HSD10 activity in fibroblast was
0.5 nmols/mg protx min (C.V. 1.4 ± SD 0.43) and a
new missense mutation was detected in HSD17B10
gen (c.628 C > T; p.P210 S) [7]. The mother was con-
firmed to be a carrier. Despite low isoleucine diet, the
global outcome was very poor. At 3 years the child
was unable to walk due to severe motor dyspraxia
and choreoathetosis. Abnormal ocular movements and
severe cognitive delay were present. At 5 years of
age, the patient died of pneumonia leading to sep-
sis, multi-organ failure, and mitochondrial dysfunction
(hyperlactacidemia, abundant Kreb’s cycle metabo-
lites in urine). Autopsy was not authorized.
CSF samples
CSF samples from our patient and controls were
obtained by lumbar puncture as previously described
[8]. First ten drops were used for routine cytochem-
ical/microbiological studies and the rest immediately
stored at −80◦C until further analysis. The study of
controls was performed in 30 subjects (age range: 21
days–5 years; average: 0.9 years, 16 boys, 14 girls)
whose CSF samples were submitted under suspicion
of central nervous system infection. Exclusion crite-
ria were diagnosis of viral or bacterial meningitis, a
chronic neurological condition, hyperproteinorrachia,
and hematic or xanthochromic CSF.
Biogenic amine metabolites (3-orthomethyldopa,
3-methoxy-4-hydroxyphenylglycol, HVA, 5hydrox-
ytryptophan, and 5-HIAA) and pterins (neopterin and
biopterin) were analyzed by HPLC with electrochemi-
cal and fluorescence detection. Results were compared
with our reference values [8].
Western blot analysis was performed for each
protein (BDNF, A, AS). TwentyL of CSF was
loaded on to the gel and proteins were separated
on 10% sodium dodecyl sulphate-polyacrylamide
gels and transferred to polyvinylidene difluoride
(PVDF) membranes (Amersham™ Hybond™–ECL;
GE Healthcare). Membranes were incubated in TBST
buffer (0.02 M Tris-base, pH 7.6, 0.8% NaCl, 0.1%
Tween 20) supplemented with 5% dried skimmed milk
for 60 min to block non-specific binding. Anti-BDNF
extracellular loop (1 : 500; Santa Cruz Biotechnology
®), anti-A (1 : 500; Santa Cruz Biotechnology ®) and
Anti AS (1 : 500; Santa Cruz Biotechnology®) antibod-
ies were added, and the preparations were incubated
at 4◦C overnight. The membranes were washed three
times with TBST buffer and then incubated with appro-
priate anti-rabbit (1 : 3,000; Promega®) or anti-mouse
(1 : 5,000; Promega®) IgG secondary antibodies at
room temperature for 1 h. The blots were then washed
six times with TBST and prepared with ECL (Pierce®
ECL Western Blotting Substract; Thermo Scientific)
for developing. Relative levels of each protein were
quantified by measuring optical densities (OD) of the
corresponding bands with Quantity One® V 4.3.1 soft-
ware.
CSF total protein concentration was measured by
standard automated procedures in an Architect ci8200
analyzer (Abbott, USA).
Samples were obtained in accordance with the
Helsinki Declaration of 1964, as revised in 2000. The
ethical committee of the Hospital Sant Joan de De´u
approved the study. Statistical analysis (linear regres-
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Fig. 1. Western blots of proteins in the patient and in controls.
sion; significance level: p < 0.05) was performed with
the SPSS 19.0 program.
RESULTS
In our patient, CSF 5-hydroxyindolacetic acid
concentration was low (133 nmol/L; C.V. 170–490)
whereas dopamine metabolites were within normal
limits (HVA: 360 nmol/L; C.V.: 344–906). BDNF, A,
and AS were detected in the CSF of the patient and
controls, at the expected molecular weight (Fig. 1).
CSF total protein concentration values in patients and
controls were within normal limits according to dif-
ferent age ranges [9]. Linear regression showed no
correlation between age and any of the studied proteins
(A: p:0,1; BDNF: p:0,2; AS: p:0,1). The expression of
BDNF and AS in the CSF of our patient showed low
values with respect to the control group, particularly
when compared with age-matched controls (Fig. 2.).
The expression of A was undetectable in the patient
whereas it was clearly present in all subjects of the con-
trol group. Given its negativity, it was repeated twice
in two CSF samples (at 3 and 4.5 years), disclosing the
same result.
DISCUSSION
HSD10 deficiency is a neurodegenerative disease
with a complex pathophysiology. Furthermore, HSD10
is a protein that may mediate the neurodegeneration
of AD through its apparent capacity to bind A (1).
Due to this affinity, we hypothesized that CSF A con-
centration in patients with HSD10 deficiency could be
abnormal and contribute to the neurobiology of this
disorder. The most striking feature of this study is
the lack of expression of A in this patient in several
samples obtained at different ages.
HSD10 catalyzes the conversion of 2-methyl-3-
hydroxybutyryl-CoA to 2-methylacetoacetyl-CoA in
the isoleucine degradation pathway, and is active
against a broad range of substrates in diverse pathways
such as steroid metabolism, GABAA receptors, and the
oxidation of other substrates (hydroxyacyl-CoAs, 2-
methyl-3-hydroxyacyl-coas) [1, 2]. Consequences of
HSD17B10 gene mutations seem to be unrelated to
accumulation of toxic metabolites in the isoleucine
pathway but rather are caused by a non-enzymatic
effect triggering mitochondrial disintegration and
apoptosis [4].
Several studies indicate that mitochondria plays an
important role in the development of AD, and this
effect could be caused by a direct interaction of Awith
MHBD (2-methyl-3-hydroxybutyryl-CoA dehydroge-
nase) [5–7]. HSD10 has a unique loop D (residues
95–114) that binds A [1]. In AD brain tissue, A
accumulates in mitochondria. Conversely its concen-
tration is low in CSF. HSD17B10 gene mutation in
our patient could have modified this binding and pro-
mote post-synaptic A trapping, thereby explaining
the apparent absence of A in the CSF.
Little is known about the neurobiology of A in
childhood. Recent studies suggest that A and its
precursor protein (APP) may play important roles
in development such as promoting synapse elimina-
tion [10, 11], pruning neurites [12], and restricting
mature forms of LTP in glutamatergic synapses [13]. In
the rodent hippocampus, A has a maximum expres-
sion during the period of most intense synaptogenesis
and synaptic elimination [14]. Therefore, persistently
low synaptic levels of A in our patient could have
impaired synaptic balance and glutamatergic transmis-
sion. Furthermore, increased post-synaptic A levels
could have disrupted synaptic plasticity and promoted
apoptosis [15–18].
BDNF is associated with dendritic growth, synap-
tic transmission [19], and the development of the
GABAergic and monoaminergic system [20]. In our
patient, BDNF low expression argues in favor of
low dendritic density and support reduced CSF con-
centration of 5-HIAA, as this neurotrophin regulates
serotonin system development. Concerning AS, this is
a presynaptic protein that binds to the SNARE com-
plex [21] and is involved in regulation of vesicle pools.
In fact, its deletion causes a reduction in the reserve
pool size [22], leading to impaired long-term poten-
tiation and synaptic plasticity. Synaptic accumulation
of AS has been related to dopaminergic loss [23]. In
our patient AS showed very low expression which
perhaps might explain why CSF dopaminergic metabo-
lites were not reduced as expected at high AS synaptic
levels.
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Fig. 2. Distribution of A, BDNF and AS values in the patient (arrows) and in controls. Units on the left are optical densities. CI: confidence
interval.
In summary, we report a patient with HSD10 defi-
ciency, undetectable CSF A expression, and low
BDNF and AS levels, which probably disrupted
critical developmental functions, contributing to
impaired synaptic plasticity, low serotoninergic trans-
mission and apparently preserved dopaminergic func-
tion.
Confirmation of these findings in other patients
would help elucidating mechanisms of synaptic dys-
function in this disease, and highlight the need for
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further studies to better understanding of the role of
A in both early and late periods of life.
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